PureTech Health PLC (STU:0VQ) Stock Price, Trades & News

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	14.16
Equity-to-Asset	0.58
Debt-to-Equity	0.06
Debt-to-EBITDA	-0.32
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.01	Distress Grey Safe
Beneish M-Score	-2.65	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	32.6
	3-Year EBITDA Growth Rate	5.8
	3-Year EPS without NRI Growth Rate	-3.1
	3-Year FCF Growth Rate	20.3
	3-Year Book Growth Rate	-15.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	28.18
	Future 3-5Y Total Revenue Growth Rate Estimate	95.81

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	65.78
	9-Day RSI	53.62
	14-Day RSI	50.45
	3-1 Month Momentum %	-1.34
	6-1 Month Momentum %	-3.92
	12-1 Month Momentum %	-2

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.59
	Quick Ratio	6.59
	Cash Ratio	5.99
	Days Sales Outstanding	152.84

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	4.6
	Shareholder Yield %	1.62

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	Operating Margin %	-2112.05
	Net Margin %	-2354.97
	EBITDA Margin %	-1321.61
	FCF Margin %	-1831.1
	OCF Margin %	-1831.1
	ROE %	-29.18
	ROA %	-19.05
	ROIC %	-37.39
	3-Year ROIIC %	7.22
	ROC (Joel Greenblatt) %	-476.52
	ROCE %	-12.2
	Years of Profitability over Past 10-Year	4
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	Shiller PE Ratio	29.64
	PS Ratio	80
	PB Ratio	1.24
	Price-to-Tangible-Book	1.31
	EV-to-EBIT	-2.12
	EV-to-EBITDA	-2.24
	EV-to-Forward-EBITDA	-0.96
	EV-to-Revenue	29.55
	EV-to-FCF	-1.46
	Price-to-GF-Value	0.23
	Price-to-Median-PS-Value	0.82
	Price-to-Net-Current-Asset-Value	4.97
	Price-to-Net-Cash	7.2
	Earnings Yield (Greenblatt) %	-47.14
	FCF Yield %	-20.88

Financials (Next Earnings Date:2026-08-28 Est.)

Annual Quarterly TTM

STU:0VQ's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

PureTech Health PLC Executives

Details

GF Value™: €6.13

STU:0VQ

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 0VQ. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4.003
	EPS (TTM) (€)	-0.396
	Beta	1.5522
	3-Year Sharpe Ratio	-0.36
	3-Year Sortino Ratio	-0.48
	Volatility %	36.93
	14-Day RSI	50.45
	14-Day ATR (€)	0.066261
	20-Day SMA (€)	1.4445
	12-1 Month Momentum %	-2
	52-Week Range (€)	1.17 - 1.65
	Shares Outstanding (Mil)	243.42

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

PureTech Health PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

PureTech Health PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings conference call for 2026	2026-08-28 09:00	In 44 days
Second quarter earnings results for 2026	2026-08-28	In 43 days
General meeting for 2026	2026-06-10 11:00	1.42 (+1.43%)
Fourth quarter earnings conference call for 2025	2026-04-29 09:00	1.47 (+4.26%)
Annual report for 2025	2026-04-29	1.47 (+4.26%)
Fourth quarter earnings results for 2025	2026-04-29	1.47 (+4.26%)
Leerink Partners Global Healthcare Conference	2026-03-11 11:20	1.41 (+2.92%)
44th Annual J.P. Morgan Healthcare Conference	2026-01-14 19:30	1.50 (+0.67%)
Second quarter earnings conference call for 2025	2025-08-28 09:00	1.51 (-3.82%)
Second quarter earnings results for 2025	2025-08-28	1.51 (-3.82%)

Show

Entries

PureTech Health PLC Frequently Asked Questions

What is PureTech Health PLC(STU:0VQ)'s stock price today?

The current price of STU:0VQ is €1.44. The 52 week high of STU:0VQ is €1.65 and 52 week low is €1.17.

When is next earnings date of PureTech Health PLC(STU:0VQ)?

The next earnings date of PureTech Health PLC(STU:0VQ) is 2026-08-28 Est..

Does PureTech Health PLC(STU:0VQ) pay dividends? If so, how much?

PureTech Health PLC(STU:0VQ) does not pay dividend.

Press Release

	Subject	Date
	PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)	2026-07-13
	Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)	2026-07-02
	PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)	2026-07-02
	PureTech Health: Results of Annual General Meeting	2026-06-10
	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers	2026-06-09
	PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference	2026-05-13
	PureTech Announces Annual Results for Year Ended December 31, 2025	2026-04-29
	PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange	2026-04-29
	PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors	2026-04-27
	PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)	2026-04-22

10/Page

Articles on PureTech Health PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.